help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dal Maso, L.
Right arrow Articles by La Vecchia, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dal Maso, L.
Right arrow Articles by La Vecchia, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 3 1160-1163
Copyright © 2004 by The Endocrine Society

Circulating Adiponectin and Endometrial Cancer Risk

Luigino Dal Maso, Livia S. A. Augustin, Aspasia Karalis, Renato Talamini, Silvia Franceschi, Dimitrios Trichopoulos, Christos S. Mantzoros and Carlo La Vecchia

Servizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico (L.D.M., L.S.A.A., R.T.), Aviano 33081, Italy; Department of Nutritional Sciences, Faculty of Medicine, University of Toronto and the Clinical Nutrition and Risk Factor Modification Center, St. Michael’s Hospital (L.S.A.A.), Toronto M5C 2T2, Canada; Human Nutrition Research Unit, Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School (A.K, C.S.M.), Boston, Massachusetts 02215; International Agency for Research on Cancer (S.F.), Lyon 69008, France; Department of Epidemiology, Harvard School of Public Health (D.T.), Boston, Massachusetts 02215; Istituto di Ricerche Farmacologiche Mario Negri (C.L.V.), Milan 20157, Italy; and Istituto di Statistica Medica e Biometria, Università degli Studi di Milano (C.L.V.), Milan 20133, Italy

Address all correspondence and requests for reprints to: Dr. Luigino Dal Maso, Servizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Institute for Cancer Research and Treatment, Via Pedemontana Occidentale, 33081 Aviano (PN), Italy. E-mail: epidemiology{at}cro.it.

Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95% confidence interval, 0.19–0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95% confidence interval, 0.14–0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).

This work was supported by the Italian Association for Cancer Research and the Italian League against Tumours.

Abbreviations: BMI, Body mass index; CI, confidence interval; IQR, interquartile range; OR, odds ratio.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
C. J Williams, N. Mitsiades, E. Sozopoulos, A. Hsi, A. Wolk, A.-P. Nifli, S. Tseleni-Balafouta, and C. S Mantzoros
Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors
Endocr. Relat. Cancer, March 1, 2008; 15(1): 289 - 299.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
D Barb, A Neuwirth, C S Mantzoros, and S P Balk
Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway
Endocr. Relat. Cancer, December 1, 2007; 14(4): 995 - 1005.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
M. Archanco, J. Gomez-Ambrosi, M. Tena-Sempere, G. Fruhbeck, and M. A. Burrell
Expression of Leptin and Adiponectin in the Rat Oviduct
J. Histochem. Cytochem., October 1, 2007; 55(10): 1027 - 1037.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
Y.-F. Tian, C.-H. Chu, M.-H. Wu, C.-L. Chang, T. Yang, Y.-C. Chou, G.-C. Hsu, C.-P. Yu, J.-C. Yu, and C.-A. Sun
Anthropometric measures, plasma adiponectin, and breast cancer risk
Endocr. Relat. Cancer, September 1, 2007; 14(3): 669 - 677.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
L. Cong, J. Gasser, J. Zhao, B. Yang, F. Li, and A. Z Zhao
Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2
Endocr. Relat. Cancer, September 1, 2007; 14(3): 713 - 720.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
D. Barb, C. J Williams, A. K Neuwirth, and C. S Mantzoros
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 858S - 866S.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. B. Richards, A. M. Valdes, K. Burling, U. C. Perks, and T. D. Spector
Serum Adiponectin and Bone Mineral Density in Women
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1517 - 1523.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. Friberg, C. S. Mantzoros, and A. Wolk
Diabetes and Risk of Endometrial Cancer: A Population-Based Prospective Cohort Study
Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 276 - 280.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Michalakis, C. J. Williams, N. Mitsiades, J. Blakeman, S. Balafouta-Tselenis, A. Giannopoulos, and C. S. Mantzoros
Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study
Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 308 - 313.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Bluher, A. M. Brennan, T. Kelesidis, J. Kratzsch, M. Fasshauer, S. Kralisch, C. J. Williams, and C. S. Mantzoros
Total and High-Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative evaluation of three assays
Diabetes Care, February 1, 2007; 30(2): 280 - 285.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
G. A. Laughlin, E. Barrett-Connor, S. May, and C. Langenberg
Association of Adiponectin with Coronary Heart Disease and Mortality: The Rancho Bernardo Study
Am. J. Epidemiol., January 15, 2007; 165(2): 164 - 174.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. E. Cust, R. Kaaks, C. Friedenreich, F. Bonnet, M. Laville, A. Lukanova, S. Rinaldi, L. Dossus, N. Slimani, E. Lundin, et al.
Plasma Adiponectin Levels and Endometrial Cancer Risk in Pre- and Postmenopausal Women
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 255 - 263.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Wang, J. B. Lam, K. S.L. Lam, J. Liu, M. C. Lam, R. L.C. Hoo, D. Wu, G. J.S. Cooper, and A. Xu
Adiponectin Modulates the Glycogen Synthase Kinase-3{beta}/{beta}-Catenin Signaling Pathway and Attenuates Mammary Tumorigenesis of MDA-MB-231 Cells in Nude Mice
Cancer Res., December 1, 2006; 66(23): 11462 - 11470.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ota, K. Ito, T. Suzuki, S. Saito, M. Tamura, S.-i. Hayashi, K. Okamura, H. Sasano, and N. Yaegashi
Peroxisome Proliferator-Activated Receptor {gamma} and Growth Inhibition by Its Ligands in Uterine Endometrial Carcinoma.
Clin. Cancer Res., July 15, 2006; 12(14): 4200 - 4208.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Takemura, Y. Osuga, T. Yamauchi, M. Kobayashi, M. Harada, T. Hirata, C. Morimoto, Y. Hirota, O. Yoshino, K. Koga, et al.
Expression of Adiponectin Receptors and Its Possible Implication in the Human Endometrium
Endocrinology, July 1, 2006; 147(7): 3203 - 3210.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
H. Motoshima, B. J. Goldstein, M. Igata, and E. Araki
AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer
J. Physiol., July 1, 2006; 574(1): 63 - 71.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
Y. Takemura, Y. Osuga, M. Harada, T. Hirata, K. Koga, C. Morimoto, Y. Hirota, O. Yoshino, T. Yano, and Y. Taketani
Serum adiponectin concentrations are decreased in women with endometriosis
Hum. Reprod., December 1, 2005; 20(12): 3510 - 3513.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
E. K. Wei, E. Giovannucci, C. S. Fuchs, W. C. Willett, and C. S. Mantzoros
Low Plasma Adiponectin Levels and Risk of Colorectal Cancer in Men: A Prospective Study
J Natl Cancer Inst, November 16, 2005; 97(22): 1688 - 1694.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Ishikawa, J. Kitayama, S. Kazama, T. Hiramatsu, K. Hatano, and H. Nagawa
Plasma Adiponectin and Gastric Cancer
Clin. Cancer Res., January 15, 2005; 11(2): 466 - 472.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society